News >

FDA Issues Complete Response Letter for Quizartinib in AML

Jason M. Broderick @jasoncology
Published: Friday, Jun 21, 2019

Antoine Yver, MD

Antoine Yver, MD
The FDA has issued a complete response letter to Daiichi Sankyo informing the company that its new drug application (NDA) would not be approved for quizartinib for the treatment of adult patients with relapsed/refractory FLT3-ITD–positive acute myeloid leukemia (AML).
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication